Floatz logo

17-beta-estradiol

Estrogen Receptor Positive Breast Cancer

AHS Cancer Control AlbertaPhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
95/ 100

Competitive context

2 Active assets in the Estrogen Receptor Positive Breast Cancer cohort.

Asset / SponsorPhaseRating
TAMOXIFEN
Dana-Farber Cancer Institute
Phase 4BBB
Tak-228
The Methodist Hospital Research Institute
Phase 2B
Vistusertib
Queen Mary University of London
Phase 2CCC
Replens
Polly A. Niravath, MD
Phase 2CCC
Prasterone
Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
Phase 2CCC
16.ALPHA.-FLUOROESTRADIOL
University of Utah
Phase 2CCC
Hydroxychloroquine
Western Regional Medical Center
Phase 1CC

Same molecule, other indications

17-beta-estradiol is also rated in:

Turner SyndromeDormant
BBB
Indicative ·
76 / 100
View asset →
Infertility, FemaleDormant
BBB
Indicative ·
75 / 100
View asset →
HypogonadismDormant
BBB
Indicative ·
75 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →